Cancer risk in individuals with major birth defects: large Nordic population based case-control study among children, adolescents, and adults.


Journal

BMJ (Clinical research ed.)
ISSN: 1756-1833
Titre abrégé: BMJ
Pays: England
ID NLM: 8900488

Informations de publication

Date de publication:
02 12 2020
Historique:
entrez: 3 12 2020
pubmed: 4 12 2020
medline: 23 12 2020
Statut: epublish

Résumé

To examine associations between birth defects and cancer from birth into adulthood. Population based nested case-control study. Nationwide health registries in Denmark, Finland, Norway, and Sweden. 62 295 cancer cases (0-46 years) and 724 542 frequency matched controls (matched on country and birth year), born between 1967 and 2014. Relative risk of cancer in relation to major birth defects, estimated as odds ratios with 99% confidence intervals from logistic regression models. Altogether, 3.5% (2160/62 295) of cases and 2.2% (15 826/724 542) of controls were born with major birth defects. The odds ratio of cancer for people with major birth defects compared with those without was 1.74 (99% confidence interval 1.63 to 1.84). For individuals with non-chromosomal birth defects, the odds ratio of cancer was 1.54 (1.44 to 1.64); for those with chromosomal anomalies, the odds ratio was 5.53 (4.67 to 6.54). Many structural birth defects were associated with later cancer in the same organ system or anatomical location, such as defects of the eye, nervous system, and urinary organs. The odds ratio of cancer increased with number of defects and decreased with age, for both non-chromosomal and chromosomal anomalies. The odds ratio of cancer in people with any non-chromosomal birth defect was lower in adults (≥20 years: 1.21, 1.09 to 1.33) than in adolescents (15-19 years: 1.58, 1.31 to 1.90) and children (0-14 years: 2.03, 1.85 to 2.23). The relative overall cancer risk among adults with chromosomal anomalies was markedly reduced from 11.3 (9.35 to 13.8) in children to 1.50 (1.01 to 2.24). Among adults, skeletal dysplasia (odds ratio 3.54, 1.54 to 8.15), nervous system defects (1.76, 1.16 to 2.65), chromosomal anomalies (1.50, 1.01 to 2.24), genital organs defects (1.43, 1.14 to 1.78), and congenital heart defects (1.28, 1.02 to 1.59) were associated with overall cancer risk. The increased risk of cancer in individuals with birth defects persisted into adulthood, both for non-chromosomal and chromosomal anomalies. Further studies on the molecular mechanisms involved are warranted.

Identifiants

pubmed: 33268348
doi: 10.1136/bmj.m4060
pmc: PMC7708828
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

m4060

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: support from Norwegian Cancer Society; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Références

Cancer Epidemiol. 2014 Aug;38(4):393-400
pubmed: 24802852
Am J Cardiol. 2016 Dec 1;118(11):1742-1750
pubmed: 27702435
JAMA Oncol. 2019 Jun 20;:
pubmed: 31219505
Cancer. 2005 May 1;103(9):1939-48
pubmed: 15770693
Acta Obstet Gynecol Scand. 2014 Feb;93(2):132-7
pubmed: 24237585
Acta Oncol. 2018 Apr;57(4):440-455
pubmed: 29226751
Lancet Oncol. 2019 Sep;20(9):1211-1225
pubmed: 31371206
BMC Med Res Methodol. 2012 Jul 11;12:96
pubmed: 22784200
Am J Epidemiol. 2012 Jun 15;175(12):1217-24
pubmed: 22534203
JAMA Oncol. 2019 Jun 20;:
pubmed: 31219523
Birth Defects Res A Clin Mol Teratol. 2016 Jul;106(7):633-42
pubmed: 26945683
JAMA Netw Open. 2019 Jul 3;2(7):e196762
pubmed: 31276179
Birth Defects Res A Clin Mol Teratol. 2011 Mar;91 Suppl 1:S44-50
pubmed: 21384529
J Natl Cancer Inst. 1951 Jun;11(6):1269-75
pubmed: 14861651
Int J Epidemiol. 1993 Dec;22(6):1189-92
pubmed: 8144304
Pediatr Clin North Am. 2015 Feb;62(1):11-25
pubmed: 25435109
PLoS One. 2013 Jul 17;8(7):e69077
pubmed: 23874873
Clin Epidemiol. 2015 Nov 17;7:449-90
pubmed: 26604824
PLoS One. 2017 Jul 27;12(7):e0181246
pubmed: 28749971
Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):500-6
pubmed: 18296646
Int J Cancer. 2006 Apr 1;118(7):1769-72
pubmed: 16231334
Acta Obstet Gynecol Scand. 2008;87(8):824-30
pubmed: 18607831
Birth Defects Res A Clin Mol Teratol. 2015 Apr;103(4):284-91
pubmed: 25808250
BMJ. 2016 Feb 25;352:i969
pubmed: 26916049
BMC Public Health. 2011 Jun 09;11:450
pubmed: 21658213
Oncotarget. 2017 Nov 3;9(1):1365-1379
pubmed: 29416701
Acta Obstet Gynecol Scand. 2007;86(12):1453-7
pubmed: 17851803
BMJ. 2017 May 30;357:j2249
pubmed: 28559234
PLoS One. 2017 Jun 8;12(6):e0179006
pubmed: 28594943

Auteurs

Dagrun Slettebø Daltveit (DS)

Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway dagrun.daltveit@uib.no.

Kari Klungsøyr (K)

Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
Division of Mental and Physical Health, Norwegian Institute of Public Health, Bergen, Norway.

Anders Engeland (A)

Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
Division of Mental and Physical Health, Norwegian Institute of Public Health, Bergen, Norway.

Anders Ekbom (A)

Unit of Clinical Epidemiology, Department of Medicine/Solna, Karolinska Institute, Stockholm, Sweden.

Mika Gissler (M)

Information Services Department, Finnish Institute for Health and Welfare (THL), Helsinki, Finland.
Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden.

Ingrid Glimelius (I)

Department of Medicine, Division of Clinical Epidemiology, Karolinska Institute, Stockholm, Sweden.
Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.

Tom Grotmol (T)

Cancer Registry of Norway, Oslo, Norway.

Laura Madanat-Harjuoja (L)

Cancer Society of Finland, Finnish Cancer Registry, Helsinki, Finland.
Department of Pediatrics, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Anne Gulbech Ording (AG)

Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.

Solbjørg Makalani Myrtveit Sæther (SMM)

Department of Health Promotion, Norwegian Institute of Public Health, Bergen, Norway.

Henrik Toft Sørensen (HT)

Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.

Rebecca Troisi (R)

Epidemiology and Biostatistics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.

Tone Bjørge (T)

Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
Cancer Registry of Norway, Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH